OBJECTIVES: The aim of the study is to analyse drug-related infectious diseases (DRID) rates for people who inject drugs (PWID) in the Pilsen Region in order to identify the main determiners of infection risk and also to provide a foundation for comparison between this region and the others in the Czech Republic. METHODS: In a descriptive cross-sectional study, we analysed the Pilsen Region's data on PWID. The data was transcribed from the 2003 to 2018 internal database of the Ulice Outreach Programme. In addition to the data regarding the testing of DRID, we analysed commercial sex work (CSW) and the PWID's duration of drug use, age and current address. The statistical analysis was performed using SPSS, primarily employing logistic regression (i.e., backward elimination method) to explore predictors of seropositivity. Moreover, we calculated its prevalence from an epidemiological perspective. RESULTS: In total, 384 PWID were tested, from which 54.7% were males, and 84.1% were from Pilsen. The average age for initiation of using drug was 19.37 years. The most used drug was methamphetamine (64.8%), 77 women (20.1%) were reported to be CSW. The prevalence of DRID was as follows: hepatitis C virus (HCV) 37.24%, syphilis 1.82%, hepatitis B virus (HBV) 0.78%, and HIV infection 0.26%. The analysis showed that men had a lower risk of syphilis than women. Individuals who started their drug use via injection had a 1.365-times higher risk of DRID in comparison to those who initiated intravenous drug use later in their drug-using lives. We identified a significant association between the drug type and the risk of HCV infection: the main predictor of seropositivity was the use of fentanyl, which posed a 1.930-times higher risk than in the case of methamphetamine. CONCLUSIONS: This study is the first descriptive cross-sectional study implemented in the Pilsen Region in the Czech Republic with a focus on the subpopulation of PWID with individual data. A high prevalence of HCV infection still persists but the prevalence of HBV and HIV infections in this study (and generally in the Czech Republic) is relatively low compared to foreign studies. Syphilis is not closely associated with injecting-drug use, but rather with the sexual behaviour of the people who use drugs intravenously. The most important predictor of seropositivity for syphilis was CSW. We also found the duration of being a CSW to be significant influence. The women who had been CSWs for less than 5 years had a significantly lower risk of syphilis than those who had prostituted for more than 5 years.

Department of Demography and Geodemography Faculty of Science Charles University Prague Czech Republic

Ulice Association in Pilsen Pilsen Czech Republic

Zobrazit více v PubMed

Mravčík V, Chomynová P, Grohmannová K, Janíková B, Černíková T, Rous Z, et. al. Annual Report on Drug Situation 2018 - Czech Republic. Prague: Office of the Government of the Czech Republic; 2019. (In Czech.)

European Monitoring Centre for Drugs and Drug Addiction. Drug-related infectious diseases in Europe: update from the EMCDDA expert network. Luxembourg: Publications Office of the European Union; 2019.

European Centre for Disease Prevention and Control. Hepatitis C: annual epidemiological report for 2017 [Internet]. Stockholm: ECDC; 2019 [cited 2020 Jan 2]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-hepatitis-C.pdf.

Zabransky T, Mravcik V, Korcisova B, Rehak V. Hepatitis C virus infection among injecting-drug users in the Czech Republic - prevalence and associated factors. Eur Addict Res. 2006;12(3):151-60. PubMed

National Monitoring Centre for Drugs and Addiction. Elimination of viral hepatitis C among drug users in the Czech Republic: starting points and action plan for the period 2019-2021. Prague: Office of the Government of the Czech Republic; 2019. (In Czech.)

European Centre for Disease Prevention and Control. Hepatitis B: annual epidemiological report for 2017 [Internet]. Stockholm: ECDC; 2019 [cited 2020 Jan 2]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/hepatitis-B-annual-epidemiological-report-2017.pdf.

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: trends and developments. Luxembourg: Publications Office of the European Union; 2019.

Malý M, Němeček V, Zákoucká H. The prevalence and spread of HIV/AIDS in the Czech Republic in 2017. Zprávy Centra Epidemiol Mikrobiol. 2018;27(6):142-53. (In Czech.)

Czech Statistical Office. Population: annual time series [Internet]. Prague: CZSO; 2020 [cited 2020 Aug 4]. Available from: https://www.czso.cz/csu/czso/obyvatelstvo_hu. (In Czech.)

Malý M, Němeček V, Zákoucká H. The prevalence and spread of HIV/AIDS in the Czech Republic in 2019. Zprávy Centra Epidemiol Mikrobiol. 2020;29(10):384-98. (In Czech.)

Malý M, Němeček V, Zákoucká H. The prevalence and spread of HIV/AIDS in the Czech Republic in 2018. Zpr Centr Epidemiol Mikrobiol. 2019;28(8):314-27. (In Czech.)

Hill MJ, Holt M, Hanscom B, Wang Z, Cardenas-Turanzas M, Latkin C. Gender and race as correlates of high risk sex behaviors among injection drug users at risk for HIV enrolled in the HPTN 037 study. Drug Alcohol Depend. 2018;183:267-74.

Hotton AL, Boodram B. Gender, transience, network partnerships and risky sexual practices among young persons who inject drugs. AIDS Behav. 2017;21(4):982-93. PubMed

Scheibe A, Makapela D, Brown B, dos Santos M, Hariga F, Virk H, et al. HIV prevalence and risk among people who inject drugs in five South African cities. Int J Drug Policy. 2016;30:107-15.

Wang M, Mao W, Zhang L, Jiang B, Xiao Y, Jia Y, et al. Methadone maintenance therapy and HIV counseling and testing are associated with lower frequency of risky behaviors among injection drug users in China. Subst Use Misuse. 2015;50(1):15-23.

European Monitoring Centre for Drugs and Drug Addiction. Differences in patterns of drug use between women and men [Internet]. Lisbon: EMCDDA; 2005 [cited 2020 Jan 2]. Available from: https://www.emcdda.europa.eu/system/files/publications/387/TDS_gender_64783.pdf.

Arpa S. Women who use drugs: issues, needs, responses, challenges and implications for policy and practice [Internet]. Lisbon: EMCDDA; 2017 [cited 2020 Jan 2]. Available from: https://www.emcdda.europa.eu/system/files/attachments/6235/EuropeanResponsesGuide2017_BackgroundPaper-Women-who-use-drugs.pdf.

Fuller CM, Borrell LN, Latkin CA, Galea S, Ompad DC, Strathdee SA, et al. Effects of race, neighborhood, and social network on age at initiation of injection drug use. Am J Public Health. 2005;95(4):689-95.

Roth AM, Armenta RA, Wagner KD, Roesch SC, Bluthenthal RN, Cuevas-Mota J, et al. Patterns of drug use, risky behavior, and health status among persons who inject drugs living in San Diego, California: a latent class analysis. Subst Use Misuse. 2015;50(2):205-14.

Kaye S, Darke SA. Comparison of the harms associated with the injection of heroin and amphetamines. Drug Alcohol Depend. 2000;58(1-2):189-95.

Mravčík V, Petrošová B, Zábranský T, Řehák V, Coufalová M. Hepatitis C virus infection among injecting drug users. Results of a study conducted among clients of low-threshold facilities in the years 2002-2005. Prague: Office of the Government of the Czech Republic; 2009. (In Czech.)

Coffin LS, Newberry A, Hagan H, Cleland CM, Des Jarlais DC, Perlman DC. Syphilis in drug users in low and middle income countries. Int J Drug Policy. 2010;21(1):20-7.

Hankins C. Sex, drugs, and gender? High time for lived experience to inform action. Int J Drug Policy. 2008;19(2):95-6.

Brookmeyer KA, Haderxhanaj LT, Hogben M, Leichliter J. Sexual risk behaviors and STI among persons who inject drugs: a national study. Prev Med. 2019;126:105779. doi: 10.1016/j.ypmed.2019.105779. PubMed DOI

Boodram B, Hotten AL, Shekhtman L, Gutfraind A, Dahari H. High-risk geographic mobility patterns among young urban and suburban persons who inject drugs and their injection network members. J Urban Health. 2018;95(1):71-82.

Tyndall MW, Patrick D, Spittal P, Li K, O'Shaughnessy MV, Schechter MT. Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STI control. Sex Transm Infect. 2002;78(Suppl 1):170-5.

Todd CS, Abed AMS, Strathdee SA, Scott PT, Botros BA, Naqibullah Safi N, et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emer Infect Dis. 2007;13(9):1327-31.

Rezaei F, Noroozi A, Armoon B, Farhoudian A, Massah O, Sharifi H, et al. Social determinants and hepatitis C among people who inject drugs in Kermanshah, Iran: socioeconomic status, homelessness, and sufficient syringe coverage. J Subst Use. 2017;22(5):474-8.

Murrill CS, Weeks H, Castrucci BC, Weinstock HS, Bell BP, Spruill C, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92(3):385-87.

Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, et al. Prevalence of HIV, hepatitis C and syphilis among injecting-drug users in Russia: a multi-city study. Addiction. 2006;101(2):252-66.